Merck Inc., (known as MSD outside of the United States and Canada), announced the FDA has accepted for priority review a supplemental new drug application (sNDA) seeking approval… read more.
The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Bosulif…. read more.
GSK plc announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Blenrep is approved for the treatment of adults with… read more.
New study results presented at the European Lung Cancer Congress (ELCC) 2025 demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations,… read more.
Gastric cancer (GC), commonly known as stomach cancer, ranks as the world’s fifth most common cancer and the third leading cause of cancer-related deaths, claiming over 784,000 lives… read more.
Roche announced today that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Itovebi (inavolisib), in combination with palbociclib (Ibrance) and… read more.
Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or… read more.
The European Medicines Agency (EMA) – the EU’s drug safety watchdog – approved 114 medicines last year, with 46 of these having a new active substance which had… read more.
Stopping the widespread use of unnecessary, potentially even harmful, cancer screenings can take up to 13 years and potentially even longer after new guidelines are put in place, according… read more.
BMS announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Phase II, single-arm study… read more.
NICE(UK): Brentuximab vedotin plus doxorubicin, dacarbazine and vinblastine is recommended, within its marketing authorisation, as an option for untreated stage 3 or 4 CD30‑positive Hodgkin lymphoma in adults. It can… read more.
A new pilot project led by McGill University researchers is showing early success in helping cancer survivors return to work, addressing an aspect of recovery they say is… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
